Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today. The collaboration could generate more than $1 billion for the CRISPR drug developer whose co-founders include Nobel laureate Jennifer Doudna, PhD, of UC Berkeley.
Possibilities include the classification of malignancies, the development of anti-obesity drugs, and the reprogramming of cells to reverse age-related diseases.
Artificial cells built with dynamically reconfigurable peptide-DNA cytoskeletons demonstrate tunable functionality.
Defense cells are constantly stimulated by healthy tissue to keep them vigilant and ready to respond to pathogens.
Senescent cells displayed more proinflammatory, metabolically deregulated, and pathology-associated signatures
Defense cells are constantly stimulated by healthy tissue to keep them vigilant and ready to respond to pathogens.
Gene therapy has undergone a renaissance in recent years, with several drugs offering beneficial, even life-saving treatments, now approved by the FDA. One example was…
Senescent cells displayed more proinflammatory, metabolically deregulated, and pathology-associated signatures
Research shows two class II HDACs regulate cells that produce an important inflammatory cytokine associated with IBD and other disorders.
Speakers at the recent CAR-TCR Summit Europe in London agreed that despite their efficacy, CAR/TCR-T cell therapy faces challenges that can result in high costs,…
A new study shows that increased levels of a protein named TP53INP2 in muscle correlate with greater muscular strength and healthier aging in humans.
